v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table summarizes the segment's financial information including the Company’s significant segment expenses:
Three Months Ended
March 31,
20262025
Revenue:
Research and development services and royalty revenue
$152,455 $25,427 
Total revenue152,455 25,427 
Cost of revenues242,325 — 
Segment operating expenses:
Research and development:
Direct program costs:
Ovaprene (1)
1,231,760 1,495,727 
Sildenafil Cream (2)
67,791 211,389 
Other advanced clinical stage programs375,763 490,562 
Phase 1 and Phase 1-ready clinical stage programs (1)
96,055 496,747 
Preclinical stage programs1,168,379 1,098,738 
Contra-R&D expenses (3)
(3,069,146)(2,618,373)
Total research and development direct program costs(129,398)1,174,790 
Indirect costs:
Personnel-related (including stock-based compensation)
1,192,862 1,492,248 
Other indirect costs28,846 78,735 
Contra R&D expenses(431,848)(448,392)
Total research and development indirect costs789,860 1,122,591 
Total research and development660,462 2,297,381 
Selling, general and administrative2,248,566 2,309,164 
Total segment operating expenses2,909,028 4,606,545 
Loss from operations(2,998,898)(4,581,118)
Interest expense199,394 134,050 
Interest income(191,688)(156,621)
Other income, net
6,715 180,240 
Net loss$(2,999,889)$(4,378,307)
(1)The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (3) below.
(2)The amount of expenses includes expenses for Sildenafil Cream, 3.6% and DARE to PLAY Sildenafil Cream.
(3)These contra R&D expenses were recognized as follows for the three months ended March 31, 2026 and 2025: (a) Ovaprene, $1.0 million, and $0.5 million, respectively; (b) Other advanced clinical stage programs, $0.4 million and $0.5 million, respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0 and $0.1 million, respectively; and (d) Preclinical stage programs, $1.7 million and $1.6 million, respectively.